Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index; 12 of the 25 sources its claims cite were checked for support.
Abstract
Context: Although some patients with hypothyroidism prefer combination therapy with liothyronine (LT3) and levothyroxine (LT4), the safety of LT3 remains unresolved. Objective: We undertook a multisource systematic review and meta-analysis of LT3 safety. Data Sources: We searched PubMed for articles relating to death, adverse events (AEs), and cardiovascular outcomes in LT3 users. We also searched AEs data in the UK Yellow Card scheme and US Food and Drug Administration Adverse Reporting System (FAERS). Data Extraction: Data was extracted independently by 2 reviewers. Out of 1814 articles identified, 52 studies were selected, comprising 21 randomized controlled trials (RCTs), 4 cohort studies, and 27 case reports. Meta-analyses were conducted for adverse outcomes in RCTs and cohort studies of combination vs monotherapy. Data Synthesis: LT3-related AEs were only reported with unregulated LT3 use or pharmacy compounding errors. LT3 and LT4 showed similar adverse severity profiles in the Yellow Card scheme. Disproportionality analysis in the FAERS database showed no increased LT3 safety signals. A meta-analysis of RCTs (n = 2128) showed a similar AEs risk for combination vs monotherapy [relative risk (RR) 1.22, 95% confidence interval (CI) 0.66-2.25]. A cohort study meta-analysis (LT3 vs LT4-only users, n = 630 254) showed no increased risk of atrial fibrillation (RR 1.10, 95% CI 0.74-1.63), heart failure (RR 1.54, 95% CI 0.95-2.47), or strokes (RR 0.86, 95% CI 0.11-6.75), but reduced mortality risk was observed for LT3 (RR 0.70, 95% CI 0.62-0.78). Conclusion: Our findings are reassuring that regulated LT3 use is not associated with the risk of death or serious AEs. More studies are needed to supplement existing data.
Overview
CoChat Summary
TL;DR
This multisource systematic review and meta-analysis found that regulated liothyronine (LT3) use was not associated with increased risk of death or serious adverse events. Serious harms were almost exclusively linked to unregulated LT3 use or pharmacy compounding errors.
Key findings
- Across 52 included studies (21 RCTs, 4 cohort studies, 27 case reports), serious LT3-related adverse events occurred mainly with compounding errors (10 cases) or unlicensed use for bodybuilding, weight loss, or fatigue (14 cases); no adverse event was reported in patients with hypothyroidism receiving supervised standard LT3 doses.
- Meta-analysis of RCTs (n = 2128) showed similar adverse-event risk for combination LT3/LT4 vs LT4 monotherapy: RR 1.22, 95% CI 0.66-2.25; only the high-dose Smith 1970 trial reported more adverse events in the combination arm.
- Cohort meta-analysis (LT3 vs LT4-only users, n = 630 254) showed no increased risk of atrial fibrillation (RR 1.10, 95% CI 0.74-1.63), heart failure (RR 1.54, 95% CI 0.95-2.47), or strokes (RR 0.86, 95% CI 0.11-6.75), but reduced all-cause mortality for LT3 (RR 0.70, 95% CI 0.62-0.78).
- Pharmacovigilance analyses found similar adverse-event severity profiles for LT3 and LT4 in the UK Yellow Card scheme, and no increased LT3 safety signal in FAERS for serious adverse events or deaths; LT4 showed an increased serious-adverse-event reporting signal (ROR 1.45, 95% CI 1.42-1.47).
Methods
- Systematic review of PubMed from inception to October 2024, plus ClinicalTrials.gov, ISRCTN, reference lists, UK Yellow Card scheme (1967-2024), and US FAERS (1968-2024); two reviewers extracted data independently.
- Included case reports/series of death or serious adverse reactions on LT3, observational studies of death/cardiovascular outcomes/severe adverse events in LT3 vs LT4 users, and RCTs of combination therapy vs LT4 monotherapy reporting adverse events; 1814 articles identified, 52 selected.
- Random-effects meta-analyses using restricted maximum likelihood for RCT adverse-event withdrawals and cohort outcomes; disproportionality analysis in FAERS using reporting odds ratios, proportional reporting ratios, and information components; cohort quality assessed with Newcastle-Ottawa Scale.
Limitations
- The paper states that pharmacovigilance databases rely on voluntary reports and are subject to underreporting, symptoms may be subjective, LT3 reporting may be affected by notoriety bias, and disproportionality analyses indicate safety signals rather than causality.
- The paper states that RCTs were often underpowered for adverse-event analysis, had short follow-up, and may be biased by underlying diagnoses and cardiovascular risk; several RCTs were excluded for not reporting adverse-event incidence, and cohort studies were heterogeneous with only 2 to 3 studies per outcome.
- The paper notes that the reduced mortality finding should be interpreted cautiously because it may reflect unexplored selection factors, and the heart failure signal was driven by a Korean cohort with high thyroid cancer prevalence and possible TSH-suppressive dosing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
12 Valid · 0 Not valid · 8 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Earlier studies in the 1960s suggested that LT3 was associated with an excess risk of thyrotoxicosis and its cardiovascular complications (69).”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Discussion
What the sources say
- Partly supportedcites [69] Smith, 1970, Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism, Br Med J sourceExperimental — accuracy not yet measured
The Results (Table III; page unavailable) report more palpitations and breathlessness during combined LT3/LT4 treatment than during LT4 alone, supporting an excess of cardiovascular symptoms. The paper does not report an excess risk of diagnosed thyrotoxicosis or establish cardiovascular complications of thyrotoxicosis; it also reports a 1970 trial, not a study from the 1960s. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, these meta-analyses were limited to trials that met criteria for efficacy analysis.”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Discussion
What the sources say
- Partly supportedcites [11] Millan-Alanis, 2021, Benefits and harms of levothyroxine/L-triiodothyronine versus levothyroxine monotherapy for adult patients with hypothyroidism. Systematic review and meta-analysis, Thyroid sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says previous meta-analyses addressed clinical outcomes and describes this review as the first to assess clinical outcomes, patient preferences, and adverse events together. It does not say that the earlier meta-analyses limited trial inclusion to studies meeting criteria for efficacy analysis; the Results describe such exclusions only for this review's own meta-analysis. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [12] Grozinsky-Glasberg, 2006, Thyroxine–triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials, J Clin Endocrinol Metab source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“AE risks in RCTs were only specifically addressed in a few previous systematic reviews (11, 12).”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Discussion
What the sources say
- Supportedcites [11] Millan-Alanis, 2021, Benefits and harms of levothyroxine/L-triiodothyronine versus levothyroxine monotherapy for adult patients with hypothyroidism. Systematic review and meta-analysis, Thyroid source
The Discussion (page unavailable) describes this as the first review to summarize observed adverse events or reactions across trials of combined thyroid therapy. The Results (page unavailable) report adverse events among randomized participants, supporting its identification as one of the few reviews specifically addressing that outcome in this treatment area. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [12] Grozinsky-Glasberg, 2006, Thyroxine–triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials, J Clin Endocrinol Metab source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These results were consistent for the ROR, proportional reporting ratio, and ICs, which are drug safety signal measures derived from 2 × 2 contingency tables in disproportionality analyses (Supplementary Table S1) (29).”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > The FAERS Database
What the sources say
- Supportedcites [29] Bahl S, Taylor PN, Premawardhana LD, et al Supplementary data for Risk of death and adverse effects in patients on Liothyronine: a multi-sourcesystematic review and meta-analysis. 2025. 10.6084/m9.figshare.29402231.v1 source
The Results section (‘The FAERS Database’) explicitly says the LT3 findings were consistent across ROR, proportional reporting ratio, and IC. It reports no LT3 signal for serious adverse events or deaths across those measures. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies were of moderate to good quality (Supplementary Table S2) (29).”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Cohort Studies
What the sources say
- Supportedcites [29] Bahl S, Taylor PN, Premawardhana LD, et al Supplementary data for Risk of death and adverse effects in patients on Liothyronine: a multi-sourcesystematic review and meta-analysis. 2025. 10.6084/m9.figshare.29402231.v1 source
The Results section (Cohort Studies) explicitly states that the included cohort studies were of moderate to good quality, citing Supplementary Table S2. The Methods section (Data Analysis) says their methodological quality was assessed using the Newcastle Ottawa Scale. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
39 more claims · 1 with their cited sources checked
Create a free account to see all 71 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These results were consistent for the ROR, proportional reporting ratio, and ICs, which are drug safety signal measures derived from 2 × 2 contingency tables in disproportionality analyses (Supplementary Table S1) (29).”
From Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Studies were of moderate to good quality (Supplementary Table S2) (29).”
From Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Both drugs showed similar AE profiles, with most reactions being general disorder events, nervous system, or psychiatric illness disorders (Supplementary Fig. S2) (29).”
From Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The lack of association persisted after excluding trials with 0 AE withdrawals (Supplementary Fig. S1) (29).”
From Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Cohort Studies
“The study by Leese et al comprised 0.4% thyroid cancer patients in the LT4 group and 22% in the LT3 group (77).”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Cohort Studies
“LT3, 400 (22% thyroid cancer), LT4 only, 34 000 (0.3% thyroid cancer)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > The FAERS Database
“−2.75”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > The FAERS Database
“−2.75 (−2.32, −2.00)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Study Selection
“resulting in a total number of 52 papers in the review. The selected studies comprised 27 case reports, 4 cohort studies, and 21 RCTs.”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Case Reports
“We identified 28 cases of serious AEs linked to LT3 in 25 reports published between 1979 and 2024 (21, 30-53). We excluded 1 report of sagittal sinus thrombosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > The FAERS Database
“−0.37”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > The FAERS Database
“−0.37 (−0.33, −0.29)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Abstract > Data Synthesis
“LT3-related AEs were only reported with unregulated LT3 use or pharmacy compounding errors.”
§ Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis > Results > Case Reports
“Manasra, 2023 (31) | 53, M | LT3 15 mcg daily, erroneously dispensed instead of MMI | Atrial fibrillation”
3 more findings
Create a free account to see every finding of this check.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“However, due to the unproven efficacy data, major international guidelines continue to recommend LT4 as the standard of care, with combination therapy only reserved for patients who have not equivocally derived symptomatic benefit from LT4 monotherapy (15-18).”
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 1×
“Adjustment for 0 counts was undertaken using a continuity correction method as described by Sweeting et al (26).”
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552 · cited 2×
“Hypothyroidism affects about 2% to 5% of the global population, with increasing prevalence in women and older adults (2).”
Self-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“However, observational studies suggest that a proportion of patients on LT4 alone continue to display impairment of psychological well-being compared with controls of similar age and sex (8, 9).”
Self-citationBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 1×
“We excluded Of the included studies, 18 trials contained information on the number of trial participants in each study arm who discontinued treatment or withdrew from trials due to AEs (54-70 , 73).”
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
Norén, G. N., Hopstadius, J., & Bate, A. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211403604 · Cited by 336 · cited 1×
“These ratios are based on the observed counts of AEs reported for a drug with respect to the expected count based on all other drugs in the database (27, 28).”
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296 · cited 3×
“A meta-analysis of RCTs by Grozinsky-Glasberg et al showed similar results to ours with no significant increase in AE risk for LT3 compared to LT4 (12).”
Murray, G. R. (1891) · BMJ · doi:10.1136/bmj.2.1606.796 · Cited by 232 · cited 1×
“Thyroid hormones have been used in the treatment of hypo-thyroidism for over a century (1).”
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 2×
“This perceived risk of harm has contributed to a reluctance to prescribe LT3 and DTE among clinicians (8).”
Self-citationConducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224 · cited 2×
“These ratios are based on the observed counts of AEs reported for a drug with respect to the expected count based on all other drugs in the database (27, 28).”
Walsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Okosieme, O., Gilbert, J., Abraham, P., Boelaert, K., Dayan, C., Gurnell, M., Leese, G., McCabe, C., Perros, P., Smith, V., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.12824 · Cited by 208 · cited 1×
“For some patients, combination treatment with LT4 and liothyronine (LT3) offers an alternative treatment approach (10).”
Self-citationClyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195
Appelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183 · cited 2×
“We excluded Of the included studies, 18 trials contained information on the number of trial participants in each study arm who discontinued treatment or withdrew from trials due to AEs (54-70 , 73).”
Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Siegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152
Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1672 · Cited by 136
Self-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Self-citationCeli, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1329 · Cited by 125
Slawik, M., Klawitter, B., Meiser, E., Schories, M., Zwermann, O., Borm, K., Peper, M., Lubrich, B., Hug, M. J., Nauck, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0297 · Cited by 113
Bunevicius, R., Jakubonien, N., Jurkevicius, R., Cernicat, J., Lašas, L., & Prange, A. J. (2002) · Endocrine · doi:10.1385/endo:18:2:129 · Cited by 111
Smith, R. N., Taylor, S. A., & Massey, J. C. (1970) · BMJ · doi:10.1136/bmj.4.5728.145 · Cited by 106 · cited 1×
“Earlier studies in the 1960s suggested that LT3 was associated with an excess risk of thyrotoxicosis and its cardiovascular complications (69).”
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
Chao, M., Jiawei, X., Xia, H., Guoming, W., Yangang, W., Xufu, W., & Shuyao, Z. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832c79e0 · Cited by 93 · cited 1×
“Although the superiority of combination therapy over LT4 alone remains unproven in randomized controlled trials (RCTs) (11-13), meta-analyses have shown that patients with hypothyroidism prefer combination therapy over LT4 monotherapy (14).”
Shakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab478 · Cited by 92
Rodriguez, T., Lavis, V. R., Meininger, J. C., Kapadia, A. S., & Stafford, L. F. (2005) · Endocrine Practice · doi:10.4158/ep.11.4.223 · Cited by 80
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationFadeyev, V. V., Morgunova, T. B., Melnichenko, G. A., & Dedov, I. I. (2010) · Hormones · doi:10.14310/horm.2002.1274 · Cited by 77
Liothyronine use in a 17 year observational population‐based study ‐ the tears study
Leese, G. P., Soto‐Pedre, E., & Donnelly, L. A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13052 · Cited by 75 · cited 5×
“The study by Leese et al comprised 0.4% thyroid cancer patients in the LT4 group and 22% in the LT3 group (77).”
InfluentialValizadeh, M., Seyyed-Majidi, M. R., Hajibeigloo, H., Momtazi, S., Musavinasab, N., & Hayatbakhsh, M. R. (2009) · Endocrine Research · doi:10.1080/07435800903156340 · Cited by 65
Millan-Alanis, J. M., González-González, J. G., Flores-Rodríguez, A., Singh Ospina, N., Maraka, S., Moreno-Peña, P. J., Brito, J. P., González-Velázquez, C., & Rodríguez-Gutiérrez, R. (2021) · Thyroid® · doi:10.1089/thy.2021.0270 · Cited by 60 · cited 4×
“Systematic reviews on LT3 safety are limited and have been confined to the analyses of short-term adverse outcomes in treatment efficacy trials (11, 12).”
InfluentialLiothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58 · cited 1×
“A potential hindrance to the use of LT3, however, is the perception that it has a less favorable safety profile than LT4 and that it exerts adverse effects on cardiovascular and bone health (19).”
Jha, S., Waghdhare, S., Reddi, R., & Bhattacharya, P. (2012) · Thyroid · doi:10.1089/thy.2011.0353 · Cited by 42
Kaminski, J., Miasaki, F. Y., Paz-Filho, G., Graf, H., & Carvalho, G. A. D. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000192 · Cited by 42
The relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Yi, W., Kim, B. H., Kim, M., Kim, J., Im, M., Ryang, S., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2022) · Thyroid · doi:10.1089/thy.2021.0634 · Cited by 36
Thyroid hormone replacement: current status and challenges
Okosieme, O. E. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.600307 · Cited by 35 · cited 2×
“Early therapy for hypothyroidism relied on desiccated thyroid extracts (DTE), which was eventually replaced by synthetic preparations in the 1960s (5).”
Self-citationLiothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality
Planck, T., Hedberg, F., Calissendorff, J., & Nilsson, A. (2021) · Thyroid® · doi:10.1089/thy.2020.0388 · Cited by 35 · cited 3×
“We identified 4 cohort studies, 1 each from Scotland (77), Sweden (78), Korea (79), and the United States (80), that re-ported morbidity and mortality data in LT3 vs LT4 users (Table 3).”
Ahluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14935 · Cited by 34
Self-citationThyrotoxic Hypokalemic Periodic Paralysis Due to Dietary Weight-Loss Supplement
Akinyemi, E., Bercovici, S., Niranjan, S., Paul, N., & Hemavathy, B. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181c960a9 · Cited by 24
Chou, H.-K., Tsao, Y., & Lin, S. (2009) · The American Journal of the Medical Sciences · doi:10.1097/01.maj.0000310783.66897.b6 · Cited by 24
Bjerkreim, B. A., Hammerstad, S. S., Gulseth, H. L., Berg, T. J., Omdal, L. J., Lee-Ødegård, S., & Eriksen, E. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816566 · Cited by 24
Brigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Liothyronine cost and prescriptions in England
Taylor, P. N., Razvi, S., Muller, I., Wass, J., Dayan, C. M., Chatterjee, K., & Boelaert, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30334-6 · Cited by 19 · cited 1×
“LT4 is now the third most prescribed medication in the UK and is likely to become even more widely used in the future (7).”
Self-citationLethal thyroid storm after uncontrolled intake of liothyronine in order to lose weight
Hartung, B., Schott, M., Daldrup, T., & Ritz-Timme, S. (2010) · International Journal of Legal Medicine · doi:10.1007/s00414-010-0423-y · Cited by 19
Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange
Shah, K., Mbughuni, M. M., Burgstaler, E. A., Block, D. R., & Winters, J. L. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21536 · Cited by 18
Krysiak, R., Szkróbka, W., & Okopień, B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1448771 · Cited by 17
Dahlberg, P. A., Karlsson, F. A., & WIDE, L. E. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92105-6 · Cited by 17
Treatment Preferences in Patients With Hypothyroidism
de Lima Beltrão, F. E., Carvalhal, G., de Almeida Beltrão, D. C., de Lima Beltrão, F. E., Ribeiro, M. O., Ettleson, M. D., Ramos, H. E., & Bianco, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae651 · Cited by 16 · cited 1×
“Although the superiority of combination therapy over LT4 alone remains unproven in randomized controlled trials (RCTs) (11-13), meta-analyses have shown that patients with hypothyroidism prefer combination therapy over LT4 monotherapy (14).”
Panikkath, R., & NUGENT, K. M. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318288a460 · Cited by 15
Biondi, B., Pucci, M., Pontieri, G., Formisano, P., & Esposito, R. (2023) · Thyroid · doi:10.1089/thy.2023.0135 · Cited by 15
Acute myocarditis in bodybuilder from coxsackievirus and thyrotoxicosis
Kwak, T., Zoubi, M. A., Aruni, B., Rios, C. R., & Kumar, S. (2016) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2016.06.005 · Cited by 11
Thyroxine-induced periodic paralysis: a rare complication of nutritional supplements
Cheema, M. A., Zain, M. A., Cheema, K., & Ullah, W. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-227946 · Cited by 9
He, Z. H., Li, Y., Trivedi, N., Gill, S., & Hennessey, J. V. (2020) · Drugs in Context · doi:10.7573/dic.2019-8-4 · Cited by 9
Warner, B. E., Woodrow, C. J., & Pal, A. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-232867 · Cited by 8
Iatrogenic Thyrotoxicosis Secondary to Compounded Liothyronine
Bains, A., Brosseau, A.-J., & Harrison, D. G. (2015) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v68i1.1426 · Cited by 8
Penna, G. C., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad629 · Cited by 8
A 29-year-old Bodybuilder with Liothyronine-induced Thyrotoxic Hypokalaemic Periodic Paralysis
van Bokhorst, Q., Krul-Poel, Y. H. M., Smit, D. L., & de Ronde, W. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002362 · Cited by 8
Massive Triiodothyronine Intoxication: Efficacy of Hemoperfusion?
Solá, E., Gómez‐Balaguer, M., Morillas, C., et al. (2002) · Thyroid · doi:10.1089/105072502320288528 · Cited by 7
Regina, Â., & Majlesi, N. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6513a4 · Cited by 7
Gottwald-Hostalek, U., & Tayrouz, Y. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2435460 · Cited by 6 · cited 3×
“A recent industry-funded review evaluated LT3 safety, including market safety information pertaining to an LT3-LT4 combination tablet (20).”
InfluentialKhan, W., van der Gugten, G., & Holmes, D. T. (2018) · Clinical mass spectrometry · doi:10.1016/j.clinms.2018.11.003 · Cited by 5
Chatterjee, S., Pedrique, G., Thomas, S., Sweeney, A. T., Daniels, G. H., & Sluss, P. (2013) · Endocrine Practice · doi:10.4158/ep12388.lt · Cited by 4
Pure T3-Thyrotoxicosis from A Mexican Weight Loss Supplement
Daniels, G. H., & Sluss, P. M. (2013) · Endocrine Practice · doi:10.4158/ep13038.lt · Cited by 4
Manasra, T. A., Shah, S. Q., Raj, S. R., et al. (2022) · CJC Open · doi:10.1016/j.cjco.2022.11.019 · Cited by 2
Stress Cardiomyopathy Due to Exogenous Thyrotoxicosis From T3 Supplementation
Shaw, K. E., & Jamrozy, A. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab048.1952 · Cited by 2 · cited 1×
“We identified 28 cases of serious AEs linked to LT3 in 25 reports published between 1979 and 2024 (21, 30-53 30-53).”
Abstract #1003897: Physician Induced Psychosis
Parimi, J. T. N., Gundluru, R., Kurukulasuriya, R., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.835 · Cited by 2
Quan, D., & Guynes, A. (2016) · Critical Care Medicine · doi:10.1097/01.ccm.0000510361.50996.51 · Cited by 1
SAT-519 Armour Thyroid and Liothyronine Combination Potentiated Thrombosis
Shin, T. H., Smith, P., & Goulden, P. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa046.968 · Cited by 1
BODYBUILDER'S CARDIOMYOPATHY: A UNIQUE CASE OF HORMONE INDUCED HEART FAILURE
Miklin, D., Marecki, G., Weintraub, S. F., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(23)03417-4 · Cited by 1
Liothyronine and a sudden unexplained death: cause or coincidence?
Bahl, S., Taylor, P., Okosieme, O., Stedman, M., Heald, A., Premawardhana, L., & Dayan, C. (2024) · Endocrine Abstracts · doi:10.1530/endoabs.101.ps1-07-02
Self-citationBahl, S., Taylor, P. N., Premawardhana, L. D., et al. (2025) · figshare · doi:10.6084/m9.figshare.29402231.v1
Self-citation
Research works printed but not linked: 1
- De La Calzada-Jeanlouie, 2011, A case of thyrotoxicosis due to a compounding error, Clin Toxicol, 49, 553
Cited by
DiStefano, J. J., Reid, K., Ghabra, K., Chen, R., & Narayanan, S. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1735282 · Cited by 1
Bartalena, L., Gallo, D., Piantanida, E., & Tanda, M. L. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2676876 · Cited by 1
“…and meta-analysis of 52 studies (21 RCTs, 4 cohort studies, 27 case reports) reported that LT3 use, if regulated, i.e., not associated to supratherapeutic doses, compounding errors, or misuse for weight loss and bodybuilding, is not bound to an increased risk of adverse events and death [163].”
Safe Optimization of Thyroid Hormone Therapy
Jonklaas, J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf512
Cao, W., Zhu, B., Jia, X., Gu, N., Zhang, Q.-Z., Wang, B.-L., Shi, M., Liu, Z., & Di, Z.-L. (2026) · Journal of clinical neuroscience · doi:10.1016/j.jocn.2026.111959
Nagayama, Y., Tachibana, S., Fukuda, T., Tatsushima, D., Mori, Y., Shindo, H., Takahashi, H., Satoh, S., Nakashima, M., & Yamashita, H. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag220
Metadata
- Authors
- Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E.
- Affiliations
- Cardiff University (GB)
- Res Consortium , Andover SP10 5RG ,
- Manchester Academic Health Science Centre (GB)
- Cwm Taf University Health Board (GB)
- Corresponding author
- Bahl, Suhani
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-08-08
- Volume
- 110
- Issue
- 11
- Pages
- 3278-3288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC12527464
- OpenAlex
- W4413105622
- Semantic Scholar
- dda0b875b6540ecdc6b1bd16e11b855d9087794a
- Cited by
- 11
- References
- 71
- Citations by year
- 2026: 9 · 2025: 2
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- liothyronine, levothyroxine, hypothyroidism, drug safety, adverse events, mortality, atrial fibrillation, heart failure, stroke, combination thyroid hormone therapy, adverse drug reaction reporting, Yellow Card Scheme, FDA Adverse Event Reporting System
- MeSH terms
- Drug Therapy, Combination, Humans, Hypothyroidism, Thyroxine, Triiodothyronine, Randomized Controlled Trials as Topic, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.